Every Prescription Weight Loss Medication Compared: The Complete 2026 Guide

From $4-a-month generic pills to cutting-edge GLP-1 injections that produce 22% body weight loss — here's how every FDA-approved weight loss medication stacks up, who each one is best for, and what they actually cost in 2026.

If you're considering prescription weight loss medication in 2026, you're facing more options than ever — and more confusion. Seven distinct medications span a range from modest appetite suppressants that have been around for decades to bioengineered peptides that fundamentally change how your brain perceives hunger.

This guide compares every FDA-approved weight loss medication head to head. No filler, no hype, just clinical data, real-world costs, and honest assessments of who benefits most from each option.

The Quick Comparison: All Weight Loss Medications at a Glance

Before diving into the details, here's the full landscape in one table. The differences in effectiveness are striking — the gap between the least and most effective options is nearly sevenfold.

The data is clear: GLP-1 medications occupy their own tier. But effectiveness isn't the only factor. Cost, side effects, duration limits, and your personal health profile all matter. Let's break each one down.

Tier 1: GLP-1 Agonists — The Gold Standard

Semaglutide (Wegovy, Ozempic)

Semaglutide changed weight loss medicine. Approved for chronic weight management in 2021 as Wegovy, it was the first medication to consistently produce double-digit percentage weight loss in clinical trials. The STEP program demonstrated 15–17% average body weight reduction at the maintenance dose — meaning a 250-pound person could expect to lose 37–42 pounds.

In January 2026, the oral Wegovy pill launched, generating over 170,000 prescriptions in its first three weeks. The pill produces roughly 15% body weight loss — slightly less than the injection — but eliminates the need for weekly self-injection. It requires daily dosing on an empty stomach with minimal water, which creates its own compliance challenges.

The drug works by mimicking GLP-1, a hormone your gut releases after eating. It slows gastric emptying, reduces appetite signals in the brain, and — crucially — seems to quiet the constant "food noise" that many people with obesity describe. That psychological shift is something no previous weight loss drug achieved.

Cost reality: Brand-name Wegovy lists at ~$1,349/month, though manufacturer programs and insurance can reduce this substantially. Compounded semaglutide through telehealth providers ranges from $99–$399/month, but the FDA's regulatory enforcement against compounders accelerated in 2025–2026. Novo Nordisk announced ~50% list price reductions effective January 2027.

Best for: Anyone with a BMI of 30+ (or 27+ with comorbidities) who wants the most effective non-surgical option and can commit to long-term treatment. Particularly strong for patients with cardiovascular risk factors given the SELECT trial data.

Tirzepatide (Zepbound, Mounjaro)

If semaglutide changed the game, tirzepatide broke the scoreboard. As a dual GLP-1/GIP receptor agonist, it targets two hunger-regulating hormones instead of one. The SURMOUNT trials produced jaw-dropping results: 20–22.5% average body weight loss, with some trial participants losing over 25%.

To put that in perspective: a 250-pound person on tirzepatide could expect to lose 50–56 pounds — approaching bariatric surgery territory without an operating room.

The dual-agonist mechanism appears to offer benefits beyond weight loss. SURMOUNT-OSA showed significant improvement in obstructive sleep apnea. Secondary analyses found consistent results across age groups, genders, and racial demographics. The medication also improved insulin sensitivity more than semaglutide in head-to-head studies, making it particularly interesting for patients with type 2 diabetes or prediabetes.

Important note for women: Tirzepatide specifically reduces the absorption of oral contraceptives. If you're taking birth control pills, your provider should discuss switching to non-oral contraception (IUD, implant) or using backup methods for 4 weeks after each dose adjustment. Semaglutide does not appear to have this interaction.

Best for: Patients seeking maximum weight loss, especially those with type 2 diabetes, insulin resistance, or sleep apnea. The gold standard when cost isn't the primary constraint.

Tier 2: Moderate-Effectiveness Oral Medications

Qsymia (Phentermine + Topiramate)

Qsymia is the strongest non-GLP-1 option, combining low-dose phentermine (appetite suppression) with topiramate (an anti-seizure drug that reduces food cravings). At 7–10% body weight loss, it sits in a meaningful middle ground — more effective than other oral options, but roughly half as effective as GLP-1 medications.

A generic version became available in May 2025, dropping prices to $50–$100/month from the $200+ brand-name cost. This made Qsymia suddenly competitive for cost-conscious patients.

The catch: Topiramate carries a black box pregnancy warning due to teratogenicity (birth defects). Women of childbearing age need reliable contraception, and the medication must be stopped immediately if pregnancy occurs. Cognitive side effects ("brain fog") are also common with topiramate, affecting about 15–20% of patients.

Best for: Patients who want better-than-phentermine results in oral form, aren't planning pregnancy, and find GLP-1 costs prohibitive. The new generic pricing makes this a reasonable stepping stone.

Contrave (Naltrexone + Bupropion)

Contrave takes a different approach entirely. Instead of targeting hunger hormones, it works on the brain's reward system. Naltrexone blocks opioid receptors (reducing the pleasurable response to food), while bupropion is an antidepressant that mildly suppresses appetite.

At 5–6% average weight loss, it's modest by GLP-1 standards. But for patients whose overeating is driven by emotional or reward-seeking patterns rather than physical hunger, Contrave can be surprisingly effective. It's also one of the few weight loss medications that can improve mood simultaneously.

Carries a black box warning for suicidal thoughts and behaviors (from the bupropion component), which requires monitoring. It's also contraindicated with seizure disorders, opioid use, and heavy alcohol consumption.

CurAccess offers Contrave at $99/month — making it one of the more affordable branded options.

Best for: Emotional eaters, patients with concurrent depression, and those who need an oral medication that addresses the psychological drivers of overeating. Often used as a starting point before GLP-1s.

Tier 3: Budget Options

Phentermine

Phentermine is the most-prescribed weight loss drug in America with roughly 740,000 monthly prescriptions. It's also the oldest — FDA-approved since 1959. As a sympathomimetic amine (related to amphetamine), it suppresses appetite through central nervous system stimulation.

At $4–$50/month generic, it's the cheapest option by far. Effectiveness averages 5–7% body weight loss, which is meaningful but modest.

The limitation: FDA approval is only for 12 weeks of use. Many providers prescribe it longer off-label, but tolerance develops over time, and it carries stimulant side effects — elevated heart rate, insomnia, dry mouth, and potential for dependency. It cannot be combined with most antidepressants.

Best for: Short-term appetite suppression on a tight budget. Some patients use it as a "bridge" medication while waiting for GLP-1 insurance approval.

Orlistat (Xenical / Alli)

Orlistat works by blocking fat absorption in the gut — roughly 30% of dietary fat passes through undigested. It's the only weight loss drug available both by prescription (Xenical, 120mg) and over the counter (Alli, 60mg).

Effectiveness is modest at 3–5% body weight loss. And the side effects are uniquely unpleasant: oily spotting, gas with discharge, urgent bowel movements, and fecal incontinence. These aren't rare complications — they're the expected mechanism of action when your body can't absorb the fat you eat.

Best for: Patients who want an OTC option without a prescription, or those who specifically want to reduce fat absorption. Most patients find the GI side effects unacceptable for long-term use.

Metformin (Off-Label)

Metformin is technically a diabetes drug, but its off-label weight loss use has expanded steadily. At $4–$20/month for generic, it's ultra-affordable. The Diabetes Prevention Program (DPP) trial showed 4.6 pounds average loss over 2.8 years — modest, but with the important finding that metformin specifically reduces visceral (belly) fat.

A 2024 discovery linked metformin to the same anti-hunger molecular pathway activated by exercise, which may explain why some patients report reduced appetite. In insulin-resistant patients (prediabetes, PCOS, metabolic syndrome), real-world data shows 5.6% body weight loss — substantially better than the general population average.

Metformin is remarkably safe for long-term use, with decades of safety data. GI side effects (diarrhea, nausea) occur in about 25% of patients but typically resolve within weeks, especially with extended-release formulations.

Best for: Patients with prediabetes, PCOS, or metabolic syndrome who want an affordable starting point with excellent long-term safety data. Often used in combination with other approaches.

What the Pipeline Holds: Coming Soon

The weight loss medication pipeline is unprecedented. Several drugs in late-stage trials could surpass even tirzepatide:

Retatrutide (Eli Lilly) — a triple agonist targeting GLP-1, GIP, and glucagon receptors — produced 28.7% body weight loss in Phase 2 trials. If that holds in Phase 3, it would be the first medication to match average bariatric surgery outcomes.

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide (an amylin analog) and showed 20.4% weight loss in the REDEFINE 2 trial — outperforming semaglutide alone by roughly 5 percentage points.

Orforglipron (Eli Lilly) is an oral GLP-1 that could be cheaper to manufacture than current injections because it's a small molecule rather than a peptide. The FDA decision is expected in 2026.

Bimagrumab + semaglutide is particularly interesting: bimagrumab is an anti-myostatin antibody that preserves muscle mass. In combination with semaglutide, patients lost 22.1% body weight with 93% of that loss coming from fat — potentially solving the muscle-loss concern that shadows all current GLP-1 therapy.

How to Choose: A Decision Framework

Choosing a weight loss medication isn't just about picking the most effective one. Here's how to think through the decision:

If maximum effectiveness matters most: Tirzepatide (20–22%) or semaglutide (15–17%) are the clear choices. Most patients should start here if cost and access allow.

If cost is the primary constraint: Generic phentermine ($4–$50/mo) or metformin ($4–$20/mo) are the starting points. Compounded GLP-1s through telehealth ($99–$399/mo) offer a middle ground.

If you're an emotional eater: Contrave targets reward pathways rather than hunger hormones. It can be combined with GLP-1s under physician guidance.

If you need an oral medication only: The Wegovy pill ($149–$299/mo), generic Qsymia ($50–$100/mo), or Contrave ($99/mo through CurAccess) are all options. Orforglipron may join them in 2026.

If you have type 2 diabetes: GLP-1s offer dual benefits (weight loss + blood sugar control). Insurance is more likely to cover Ozempic or Mounjaro when prescribed for diabetes, even though Wegovy and Zepbound are the weight loss-labeled versions.

If you want the safest long-term option: Metformin has decades of safety data. GLP-1 medications have excellent safety profiles over several years but lack the multi-decade track record.

Frequently Asked Questions

The Bottom Line

The weight loss medication landscape in 2026 has a clear hierarchy. GLP-1 agonists — semaglutide and tirzepatide — sit in a class of their own, producing three to seven times more weight loss than older medications. The pipeline promises even more effective options within the next one to three years.

But "most effective" doesn't always mean "best for you." Your budget, health conditions, medication tolerance, and treatment goals all factor into the decision. A conversation with a licensed provider — whether in person or through telehealth — is the right starting point.

What's no longer in question is whether medications work for weight loss. They do. The question is which one fits your life.